Sebastien Hazard
Chief Tech/Sci/R&D Officer at IMUNON, INC.
Net worth: 32 800 $ as of 31/03/2024
Profile
Sebastien Hazard is currently the Chief Medical Officer & Executive Vice President at Imunon, Inc. Prior to his current position, he held the role of Senior Medical Director-Clinical Development at Tesaro, Inc. from 2016 to 2019.
From 2019 to 2021, he served as the Head-Clinical Development at GSK Plc.
Dr. Hazard then joined Bicycle Therapeutics Plc in 2021 as the Senior VP & Head-Clinical Development, a position he held until 2023.
Hazard obtained an MBA from INSEAD.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMUNON, INC.
0.21% | 07/12/2023 | 20,000 ( 0.21% ) | 32 800 $ | 31/03/2024 |
Sebastien Hazard active positions
| Companies | Position | Start |
|---|---|---|
| IMUNON, INC. | Chief Tech/Sci/R&D Officer | 11/12/2023 |
Former positions of Sebastien Hazard
| Companies | Position | End |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | 01/09/2023 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 01/04/2021 |
| TESARO INC | Chief Tech/Sci/R&D Officer | 01/05/2019 |
Training of Sebastien Hazard
| INSEAD | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| IMUNON, INC. | Health Technology |
| GSK PLC | Health Technology |
| BICYCLE THERAPEUTICS PLC | Health Technology |
| Private companies | 1 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Sebastien Hazard
